Clinical Trials Logo

Clinical Trial Summary

Since December 2019, a new agent, the SARS-Cov-2 coronavirus has been rapidly spreading from China to other countries causing an international outbreak of respiratory illnesses named COVID-19. In France, the first cases have been reported at the end of January with more than 60000 cases reported since then. A significant proportion (20-30%) of hospitalized COVID-19 patients will be admitted to intensive care unit. However, few data are available for this special population in France. We conduct a large observational cohort of ICU suspected or proven COVID-19 patients that will enable to describe the initial management of COVID 19 patients admitted to ICU and to identify factors correlated to clinical outcome.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04340466
Study type Observational [Patient Registry]
Source Centre Hospitalier Universitaire de Nimes
Contact
Status Completed
Phase
Start date April 3, 2020
Completion date July 3, 2020

See also
  Status Clinical Trial Phase
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04578210 - Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia Phase 1/Phase 2
Completed NCT05065827 - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Completed NCT04720794 - A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion N/A
Enrolling by invitation NCT04659486 - Adolescents With COVID-19/MIS-C at HCFMUSP N/A
Completed NCT04598620 - Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate
Completed NCT05517941 - Effect of Active Cycle Breathing Technique Along With Incentive Spirometer on COVID19 Patient N/A
Recruiting NCT04565782 - Corona Virus Infection Among Liver Transplant Recipients
Recruiting NCT04480333 - Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831 Phase 1
Active, not recruiting NCT04558476 - Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation Phase 2
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Completed NCT05639998 - BBV152/BBV154 Heterologus Prime-Boost Study Phase 2
Withdrawn NCT04386447 - Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 Phase 2
Completed NCT05736926 - Anal Fissure Among Survivors of COVID-19 Virus Infection.
Completed NCT04523246 - Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents Early Phase 1
Recruiting NCT04583566 - Differential Expression of Cytokines, Transcriptome and miRNA in Coronavirus Disease 2019 (COVID-19) Egyptian's Patients
Completed NCT04643678 - Anakinra in the Management of COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04579588 - Understanding Immunity to the Flu Vaccine in COVID-19 Patients
Terminated NCT03331445 - Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections Phase 2
Recruiting NCT04573348 - T Cells Response to SARS COV 2 Peptides